A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Inclusion Criteria: * Age ≥ 19 * Patients who understood the contents and purpose of this trial and signed informed consent form * Patients with essential hypertension and dyslipidemia Exclusion Criteria: * Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP * Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg * Concomitant administration of cyclosporine * Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy * Hereditary angioedema or medical history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor blockers * Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin * CPK normal range \> 2 times * Secondary hypertension and suspected secondary hypertension * Orthostatic hypotension with symptoms * Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times) * Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times) * Active gout or hyperuricemia(uric acid ≥ 9mg/dL) * IDDM or uncontrolled type 2 diabetes mellitus (HbA1c \> 9%) * Ventricular arrhythmia * Medical history * Severe heart disease(heart failure of NYHA class III-IV) * Severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertensive encephalopathy, transient cerebral ischemic attack(TIA) * Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant stenosis in aortic valve or mitral valve * Ischemic heart disease(myocardial infarction, angina) within 6months * Angioplasty or coronary artery bypass graft(CABG) surgery within 6months